<DOC>
	<DOCNO>NCT00508651</DOCNO>
	<brief_summary>The primary objective study describe safety tolerability 3 dose MEDI-560 10^5 TCID50 administer child 6 &lt; 12 month age HPIV3 ( human parainfluenza virus type 3 ) seronegative baseline infant 1 &lt; 3 month age regardless baseline serostatus .</brief_summary>
	<brief_title>A Phase 1/2A Study Evaluate Safety , Immunogenicity , Shedding MEDI-560 Infants 1 &lt; 12 Months Age</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , multidose Phase 1/2a multicenter study design evaluate safety , tolerability , viral shedding , immunogenicity , genotypic phenotypic stability MEDI-560 infant 1 &lt; 12 month age . Three dose MEDI-560 dosage level 10^5 TCID50 administer 0 , 2 , 4 month enrollment 30-participant cohort 6 &lt; 12 month-old HPIV3 seronegative child randomize 2:1 MEDI-560 v placebo . A second 160-participant cohort 1 &lt; 3 month-old infant screen baseline serostatus plan open enrollment reason safety . Participants follow safety 180 day post last dose . Nasal wash specimen collect screen Days 7 , 12 , 28 follow dose unscheduled illness visit assess vaccine virus shed genotypic phenotypic stability shed vaccine virus . Blood collect screen determine eligibility prior Dose 1 baseline serostatus . Blood assessment antibody HPIV3 collect approximately 7 12 day Dose 1 Dose 3 1 month dose antibody PIV3 .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Male female whose age day randomization fall within one two age cohort : Cohort 1 : 6 &lt; 12 month ( ≥ 6 month age yet reach 1st year birthday ) ; Cohort 2 : 1 &lt; 3 month ( &gt; 28 day age yet reach 3rd month birthday ) 2 . Cohort 1 : Participant seronegative HPIV3 screening determine ELISA ; legal representative willing provide access data document participant screen another MedImmune trial write informed consent obtain , participant seronegative HPIV3 within 21 day prior randomization MICP150 determine ELISA MedImmune 3 . Participant product normal full term pregnancy , defined 3642 week gestation 4 . Participant general good health 5 . Participant 's legal representative available telephone 6 . Written inform consent Health Insurance Portability Accountability Act authorization ( applicable ) obtain participant 's legal representative 7 . Participant 's legal representative able understand comply requirement protocol judge investigator 8 . Participant available complete followup period 180 day final dose investigational product require protocol 9 . Participant 's legal representative willing able bring subject study site evaluation respiratory illness accordance protocol 1 . Any fever ( ≥ 100.4°F [ ≥ 38.0°C ] , regardless route ) low respiratory illness within 7 day prior randomization 2 . Moderate severe nasal congestion investigator 's opinion could prevent intranasal delivery investigational product 3 . Cohort 1 : weight &lt; fifth percentile age day randomization 4 . Cohort 2 : history low birthweight ( ie , &lt; 2,500 gram birth ) weight &lt; fifth percentile age day randomization 5 . Any drug therapy ( chronic ) within 7 day prior randomization expect receipt protocolspecified blood collection 28 day investigational product dosing , except infrequent use overthecounter medication pain reliever permit accord judgment investigator 6 . Any current expect receipt immunosuppressive agent include steroid ( ≥ 2 mg/kg per day prednisone equivalent , ≥ 20 mg/day participant weigh &gt; 10 kg , give daily alternate day ≥ 14 day ) ; child category receive investigational product immunosuppressive agent include corticosteroid therapy discontinue ≥ 30 day ; use topical steroid permit accord judgment investigator 7 . History receipt blood transfusion expect receipt 30 day final investigational product dose 8 . History receipt immunoglobulin product expect receipt 30 day final investigational product dose 9 . Receipt investigational drug within 60 day prior randomization expect receipt 30 day final investigational product dose 10 . Receipt live virus vaccine ( exclude rotavirus vaccine ) within 28 day prior randomization expect receipt within 28day window around dose 11 . Receipt inactivate ( eg , nonlive ) vaccine rotavirus vaccine within 14 day prior randomization expect receipt within 14day window around dose 12 . Known suspected immunodeficiency , include human immunodeficiency virus 13 . Living home enrol classroom day care infant &lt; 24 month age within 28 day dose ( one child per household may enrol study ) 14 . Contact pregnant caregiver within 28 day dose 15 . Household contact immunocompromised person within 28 day dose ; participant also avoid close contact immunocompromised individual least 28 day investigational product dose 16 . Household contact within 28 day dose healthcare worker direct patient care responsibility household contact within 28 day dose someone day care provider preschool teacher child &lt; 24 month age 17 . History allergic reaction component investigational product 18 . Previous medical history evidence intercurrent chronic illness , opinion investigator , may compromise safety participant 19 . Known suspect active chronic hepatitis infection 20 . History medical diagnosis asthma , reactive airway disease , wheeze require medication , bronchoconstriction treatment β2 agonist ( eg , albuterol ) , cystic fibrosis , chronic lung disease prematurity ( eg , bronchopulmonary dysplasia ) , chronic pulmonary disease , medically confirm apnea , hospitalization respiratory illness mechanical ventilation 21 . A family member household contact employee research center otherwise involved conduct study 22 . Any condition , opinion investigator , might interfere investigational product evaluation</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>11 Months</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>parainfluenza virus , child , vaccine</keyword>
</DOC>